Amedisys’ strong presence in hospital at home, home health, hospice, palliative, and high-acuity care services and Option Care Health's existing home and alternate site infusion services will create a leader in end-to-end home-based health solutions.
Following the closing of the transaction, Option Care Health expects to be well positioned to serve as a single partner to heath systems with its offerings across the alternate site care spectrum. Together, the companies are expected to expand relationships with commercial and government payers to deliver more affordable cost of care.
The combined platform will create a system of field-based clinicians with processes in place to better optimize staffing and retention to help meet growing market demand.
Option Care Health and Amedisys, along with their stakeholders, are expected to benefit from combined patient data sets across a critical population, enhancing opportunities to proactively identify interventions, increase patient engagement, enhance clinical protocols and offer value-based care.
Amedisys stockholders will receive 3.0213 shares of Option Care Health common stock for each share of Amedisys common stock they hold at the closing of the transaction, the equivalent of $97.38 per Amedisys share based on Option Care Health's closing stock price on May 2, 2023
Consideration represents an approximate 26% premium to Amedisys stockholders based on the closing stock price of Amedisys on May 2, 2023
Upon closing Option Care Health stockholders will own approximately 64.5% of the combined company, and Amedisys stockholders will own approximately 35.5%